# A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes

> **NCT01674348** · PHASE2 · TERMINATED · sponsor: **Piramal Enterprises Limited** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** P2202
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01674348
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-12
- **Final completion:** 2013-07
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Due to non-recruitment, the study is being halted. There are no major safety or tolerability concerns in the study conducted so far.
- **Last updated:** 2013-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01674348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01674348, "A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01674348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*